Evidence map›Paper›PMID 42422019›Full record

ArticleInnovation (Cambridge (Mass.))2026

Design and development of novel EGFR inhibitors spanning all subgroups of EGFR mutations in non-small cell lung cancer.

Caolin Wang, Yiting Cen, Manzhan Zhang, Jiahong Tang, Zitong Yan, Lijuan Xie, Deheng Sun, Wei Zhou, Jie Wang, Panpan Yu and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Innovation (Cambridge (Mass.)), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Caolin WangSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Yiting CenSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Manzhan ZhangSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Jiahong TangSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Zitong YanSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Lijuan XieSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Deheng SunSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Wei ZhouSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Jie WangSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Panpan YuSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Zhen YuanSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Junyi WangSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Zeyan HuSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Tingyuan YangSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Wenjie ShaSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Shiliang LiInnovation Center for AI and Drug Discovery, School of Pharmacy, East China Normal University, Shanghai 200062, China.
Zhenjiang ZhaoSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Yufang XuSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Zhuo ChenSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.
Honglin LiSchool of Pharmacy, East China University of Science and Technology, Shanghai 200237, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EGFR mutations are common in non-small cell lung cancer (NSCLC), with classical mutations (L858R and exon 19 deletions [Ex19del]) and T790M mutation responsive to three generations of EGFR inhibitors (TKIs). However, the other 30% EGFR mutations, which are classified into exon 20 insertions (Ex20ins) and PACC (P loop/αC-helix compressing) often confer resistance to current TKIs, thereby inducing limited clinical efficacy. In this article, a conserved subpocket behind the ATP-binding domain was detected with our precursor from in-house virtual screening and structural superposition against all subgroups of mutations. This subpocket was utilized combining with traditional ATP pocket in the design and optimization of pan-EGFR inhibitors. The representative compound

Indexed as

drug designEGFR Ex20insEGFR inhibitorNSCLCPACC

Identifiers

PMID42422019
PMCPMC13343436

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.